Clinical trials: Recurrent Herpes Labialis
- Condition Recurrent Herpes Labialis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Recurrent Herpes Simplex Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis
Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01321359)
- Testing
- Vehicle versus NB-001
- Where
- 35 sites in United States
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
- Trial name
- NCT00453401
- Testing
- NB-001
- Where
- 28 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating.
- Trial name
- NCT00230867
- Testing
- iontophoretic acyclovir
- Where
- 26 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Transport Pharmaceuticals
Recurrent Herpes Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)
The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01324466)
- Testing
- NB-001, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation